Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

dader schreef op 29 maart 2018 21:03:

[...]
Zij ipv hij

quote:

Nachtzwaluw schreef op 29 maart 2018 15:24:

[...]
Ruud
je hebt gelijk mbt bijwerkingen maar ze (Shire) krijgt het linksom of rechtsom toch voor elkaar, zie PB van hun vandaag: www.shire.com/en/newsroom/2018/march/...
Zij hebben macht hoor, onderschat dat niet. En bijwerkingen of niet; ze liggen er niet wakker van, gewoon er door drukken die hap en de andere spelers hebben het nakijken. Als dan na een paar jaar blijkt van oeps er gaat iets mis dan is Pharming allang exit. Lana heeft zeker niet mijn voorkeur maar andere machten hebben het voor het zeggen (lees ook dat stuk eens over de corruptie binnen de FDA, ben de link effe kwijt).

• Shire's products may not be a commercial success;

• increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire's future revenues, financial condition and results of operations;
  

• Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes. Any disruption to the supply chain for any of Shire's products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;

• the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  

• the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity;
  

• Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  

• the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire's revenues, financial conditions or results of operations;
  

• failure to comply with laws and regulations governing the sales and marketing of its products could materially impact Shire's revenues and profitability;

• Shire's products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;

• Shire's patented products are subject to significant competition from generics;

• adverse outcomes in legal matters, tax audits and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the Shire's revenues, financial condition or results of operations;

• Shire may fail to obtain, maintain, enforce or defend the intellectual property rights required to conduct its business;

• Shire faces intense competition for highly qualified personnel from other companies and organizations;

• failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect the Shire's financial condition and results of operations;

• Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;

• a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers;

• changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;

• Shire is subject to evolving and complex tax laws, which may result in additional liabilities that may adversely affect the Shire's financial condition or results of operations;

• if a marketed product fails to work effectively or causes adverse side effects, this could result in damage to Shire's reputation, the withdrawal of the product and legal action against Shire;

• Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire's revenues, financial condition or results of operations;

• Shire faces risks relating to the expected exit of the United Kingdom from the European Union;

• Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which has increased its borrowing costs and may decrease its business flexibility;

• Shire's ongoing strategic review of its Neuroscience franchise may distract management and employees and may not lead to improved operating performance or financial results; there can be no guarantee that, once completed, Shire's strategic review will result in any additional strategic changes beyond those that have already been announced;

quote:

KarenT schreef op 29 maart 2018 17:46:

[...]

Niets met kei te maken voda, zoals ik vanmorgen al zei, 1.14 is een koopje en herstel naar 1.20 (ok iets lager dan) is bijna zekerheid. Die kans kan je dan niet laten liggen

quote:

kingkong1 schreef op 29 maart 2018 18:21:

[...]

Goed gedaan Kingkong

quote:

Gilougil schreef op 30 maart 2018 02:23:

Hoop .100% op 1 jaar.... ?

quote:

maliqun61 schreef op 30 maart 2018 08:44:

Even aantal shorts via OTC bijgewerkt.
In de periode 28 februari tm 15 maart: van 2.650.901 naar 3.471.352. Toename aantal shorts met 820.451 stuks, oftewel ca 0,14% uitstaande hoeveelheid aandelen.

Medingen shortposities bij AFM:
publicatiedatum 28 februari : 2,03%
publicatiedatum 16 maart: 2,17%

Nog steeds niet onder de indruk van MW en consorten;-)

quote:

maliqun61 schreef op 30 maart 2018 08:25:

Melding AFM 1 betreft J. Egberts:
Aantal effecten van 210.000 naar 490.000
www.afm.nl/nl-NL/Professionals/regist...

Melding AFM 2 betreft J. Blaak:
aantal effecten van 120.000 naar 115.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 3 betreft RJM Wright
aantal effecten van 220.000 naar 241.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 4 betreft S de Vries
aantal opties van 12.900.000 naar 10.400.000
aantal effecten van 1.695.205 naar 2.895.939
www.afm.nl/nl-NL/Professionals/regist...

Meldingsdatum 26 maart

quote:

JacobusJW schreef op 30 maart 2018 08:47:

[...]

Volgens het shortsell register heeft MW per 20 maart 1,99% en PDT per 9 maart 0,75%.

quote:

LT belegger schreef op 30 maart 2018 00:43:

[...]

Ze hebben voor de zekerheid de risico's van Lanadelumab toch ook maar in het persbericht gezet Nachtzwaluw:

Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

• Shire's products may not be a commercial success;

• increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire's future revenues, financial condition and results of operations;
  

• Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes. Any disruption to the supply chain for any of Shire's products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;

• the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  

• the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity;
  

• Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  

• the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire's revenues, financial conditions or results of operations;
  

• failure to comply with laws and regulations governing the sales and marketing of its products could materially impact Shire's revenues and profitability;

• Shire's products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;

• Shire's patented products are subject to significant competition from generics;

• adverse outcomes in legal matters, tax audits and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the Shire's revenues, financial condition or results of operations;

• Shire may fail to obtain, maintain, enforce or defend the intellectual property rights required to conduct its business;

• Shire faces intense competition for highly qualified personnel from other companies and organizations;

• failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect the Shire's financial condition and results of operations;

• Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;

• a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers;

• changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;

• Shire is subject to evolving and complex tax laws, which may result in additional liabilities that may adversely affect the Shire's financial condition or results of operations;

• if a marketed product fails to work effectively or causes adverse side effects, this could result in damage to Shire's reputation, the withdrawal of the product and legal action against Shire;

• Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire's revenues, financial condition or results of operations;

• Shire faces risks relating to the expected exit of the United Kingdom from the European Union;

• Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which has increased its borrowing costs and may decrease its business flexibility;

• Shire's ongoing strategic review of its Neuroscience franchise may distract management and employees and may not lead to improved operating performance or financial results; there can be no guarantee that, once completed, Shire's strategic review will result in any additional strategic changes beyond those that have already been announced;

AND

A further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in "ITEM1A: Risk Factors", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.

quote:

maliqun61 schreef op 30 maart 2018 08:25:

Melding AFM 1 betreft J. Egberts:
Aantal effecten van 210.000 naar 490.000
www.afm.nl/nl-NL/Professionals/regist...

Melding AFM 2 betreft J. Blaak:
aantal effecten van 120.000 naar 115.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 3 betreft RJM Wright
aantal effecten van 220.000 naar 241.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 4 betreft S de Vries
aantal opties van 12.900.000 naar 10.400.000
aantal effecten van 1.695.205 naar 2.895.939
www.afm.nl/nl-NL/Professionals/regist...

Meldingsdatum 26 maart

quote:

Techspec schreef op 30 maart 2018 01:07:

[...]

Goed gedaan hoor!

Gezien de volatiliteit van de afgelopen periode heb ik vandaag ook een keer 50K stuks gekocht op €1,14 voor de KT en vandaag ook weer verkocht op €1,185. Ik dacht bij mezelf, laat ik maar profiteren van het gerommel door shorters en eens wat verdienen aan Pharming en hopelijk was dit ten koste van de shorters. Toch nog even bijna 4% rendement behaald.

Mijn aanzienlijke LT portefeuille in Pharming blijft uiteraard ongemoeid in afwachting van al het moois dat nog gaat komen.

quote:

dader schreef op 30 maart 2018 09:07:

[...]
Achteraf dom gelul,dit soort praatjes vaker gelezen als het een daggie in het groen is geeindigd .
Hadden jullie toevallig ook om 09.00 uur esperite gekocht op 0.38 en op 0.47 verkocht
Fijne feestdagen en tot dinsdag na 07.00 uur

quote:

maliqun61 schreef op 30 maart 2018 08:25:

Melding AFM 1 betreft J. Egberts:
Aantal effecten van 210.000 naar 490.000
www.afm.nl/nl-NL/Professionals/regist...

Melding AFM 2 betreft J. Blaak:
aantal effecten van 120.000 naar 115.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 3 betreft RJM Wright
aantal effecten van 220.000 naar 241.000
www.afm.nl/nl-NL/Professionals/regist...

Melding 4 betreft S de Vries
aantal opties van 12.900.000 naar 10.400.000
aantal effecten van 1.695.205 naar 2.895.939
www.afm.nl/nl-NL/Professionals/regist...

Meldingsdatum 26 maart

• Hij heeft 374.266 aandelen verkocht op € 1,22 totaal € 456.604

• Hij heeft 925.999 aandelen verkocht op 1,18 totaal € 1.092.679

• Hij heeft 2,5 miljoen opties op € 0,09 uitgeoefend totaal € 225.000

quote:

Techspec schreef op 30 maart 2018 01:07:

[...]

Goed gedaan hoor!

Gezien de volatiliteit van de afgelopen periode heb ik vandaag ook een keer 50K stuks gekocht op €1,14 voor de KT en vandaag ook weer verkocht op €1,185. Ik dacht bij mezelf, laat ik maar profiteren van het gerommel door shorters en eens wat verdienen aan Pharming en hopelijk was dit ten koste van de shorters. Toch nog even bijna 4% rendement behaald.

Mijn aanzienlijke LT portefeuille in Pharming blijft uiteraard ongemoeid in afwachting van al het moois dat nog gaat komen.

quote:

AnalytischDenker schreef op 30 maart 2018 09:19:

[...]

Sijmen de Vries heeft dus gecashd !!!!!

• Hij heeft 374.266 aandelen verkocht op € 1,22 totaal € 456.604

• Hij heeft 925.999 aandelen verkocht op 1,18 totaal € 1.092.679

• Hij heeft 2,5 miljoen opties op € 0,09 uitgeoefend totaal € 225.000

Per saldo heeft hij dus € 1,55 miljoen ontvangen.

Natuurlijk hij moet ook zijn belasting kunnen betalen, is dan de reden.

En nee, we zijn nog lang niet door de opties heen. Nog ongeveer 40 miljoen te gaan.